Biopharma Dealmaking in Oncology: Trends and Projections

Oncology remains the dominant force in biopharmaceutical research and development (R&D) dealmaking, attracting significant investment despite evolving market dynamics. While deal numbers have fluctuated, the overall value of these partnerships remains robust, signaling a continued commitment to advancing cancer treatments. This article examines recent trends in oncology-focused biopharma deals, analyzes the factors driving investment, and provides a forward-looking perspective on the landscape.

The Rise of Oncology Partnerships

For several years, oncology has consistently captured the largest share of biopharma deal value. Investments in this sector have exceeded $200 billion in recent years, with $100 billion recorded in 2022 alone. Although the peak in deal volume occurred in 2020 and 2021, the average value of deals has increased, particularly in 2024.

2024 Deal Landscape: Value and Focus

In 2024, the top ten biopharma partnerships reached a combined potential value of $31 billion, with cancer therapies featuring prominently in six of those deals [1]. This demonstrates a sustained appetite for innovation in oncology, even amidst broader economic pressures and patent expiration concerns.

Facing the threat of patent expirations and generic competition, biopharma companies increased their investment in licensing deals by 33% on average in 2024 compared to 2023, specifically targeting oncology [4]. Keytruda, Eliquis, and other blockbuster cancer therapies are facing patent cliffs, driving the need for pipeline replenishment.

Key Areas of Investment

Several key areas are driving oncology R&D dealmaking:

• Protein Drugs & Oncology: Deals like Novartis’s $2.89 billion partnership with PeptiDream and its $3 billion collaboration with Dren Bio highlight the focus on radioligand therapies and bispecific antibodies [1]. Instil Bio’s $2 billion collaboration with ImmuneOnco Biopharmaceuticals emphasizes bispecifics for solid tumors.
• Precision Medicine: Roche’s $2 billion partnership with MOMA Therapeutics demonstrates a commitment to next-generation precision oncology tools targeting challenging enzymes [1].
• Cardiovascular Innovation: While oncology dominates, deals like AstraZeneca’s $2 billion agreement with CSPC indicate investment in other therapeutic areas [1].

Deal Stages and Trends

Most deals are occurring at the platform/discovery stage, indicating a willingness to invest early in promising assets. Upfront payments for Phase II lead drugs have increased significantly, jumping over 460% from 2022 to 2024 [4]. This suggests a growing confidence in early-stage innovation and a competitive landscape for promising therapies.

Looking Ahead

Deal numbers and values for 2024 are projected to remain comparable to 2023, with approximately 200 deals expected by year-end. The biopharmaceutical industry is still in a recovery phase, but the commitment to oncology R&D dealmaking remains strong. The need to address patent expirations and replenish pipelines will continue to drive investment in novel therapies and strategic partnerships. The increasing value of deals, particularly at earlier stages, suggests a focus on high-potential, innovative assets.

Key Takeaways

• Oncology continues to be the leading area for biopharma dealmaking.
• Deal values are increasing, despite fluctuations in deal volume.
• Early-stage investments are gaining prominence, with significant increases in upfront payments.
• Patent expirations are driving the need for pipeline replenishment through licensing deals.